Voysey tries never to complain without offering some constructive suggestion. In a similar spirit, we suggest that the changes needed are systemic. Canada's parliamentary health committee has just released an excellent report,3 calling for 3 key changes to drug regulation: better monitoring and public access to information on clinical trials, conditional drug approvals coupled with improved post-market surveillance and enforcement of Canada's law prohibiting direct-to-consumer advertising of prescription drugs. These changes are badly needed and would go a long way toward preventing similar future harm. Canada is of course not the only country in which drug regulation needs a radical overhaul: regulatory agencies in Europe and the United States also fail to adequately consider the public interest.4